Ads
related to: prostate cancer trials- Prostate Cancer
Discover Prostate Cancer Treatments
Download our Prostate Cancer Guide
- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Prostate Cancer
Search results
Results from the WOW.Com Content Network
The trial investigates new approaches for men with metastatic and locally advanced prostate cancer. [1] 117 hospitals in the UK and Switzerland are involved with over 10,000 men are expected to take part in the trial. [2] The men are randomly assigned to one of a number of "arms". The primary outcome by which the arms were judged is overall ...
Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical trials. A team at Heriot-Watt University, Edinburgh, leading the ...
PROSTVAC is being developed in partnership with the National Cancer Institute under a formal Cooperative Research and Development Agreement and has been the subject of multiple ongoing and completed clinical studies, including the global Phase 3 PROSPECT study underway in patients with asymptomatic or minimally symptomatic metastatic prostate cancer (mCRPC). [2]
The Scandinavian Prostate Cancer Group (SPCG) is a group of scientific researchers who have conducted a series of clinical trials of treatments for prostate cancer. [ 1 ] [ 2 ] The group was founded in 1981 and the first study, SPCG-1, began in 1984.
TD Cowen analyst Marc Frahm said the data establishes that Janux's prostate cancer therapy, JANX007, has multi-billion-dollar potential. Janux Therapeutics surges on upbeat trial data for prostate ...
The programme consisted of three large randomized, double-blind, placebo-controlled trials in which a total of 8,113 men with localized or locally advanced prostate cancer were treated with 150 mg/day bicalutamide plus standard care (watchful waiting, radical prostatectomy, or radiation therapy) (n=4052) or given placebo (standard care alone ...
Prostate cancer is now the most common cancer in the UK, according to new analysis - as a leading charity renewed its calls for a national screening program.. NHS data found 55,033 men were ...
It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]
Ads
related to: prostate cancer trials